Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation

By sjmartinez • February 9, 2024

abatacept, acitretin, adalimumab, apremilast, biologics, brodalumab, certolizumab, cyclosporine, deucravacitinib, etanercept, golimumab, guselkumab, infliximab, ixekizumab, methotrexate, psoriasis, psoriatic arthritis, recommendation, risankizumab, secukinumab, tildrakizumab, tofacitinib, ustekinumab, vaccination, vaccines,

Tags: abatacept, acitretin, adalimumab, apremilast, Biologics, brodalumab, certolizumab, cyclosporine, Dermatology, deucravacitinib, etanercept, golimumab, guselkumab, infliximab, ixekizumab, methotrexate, psoriasis, psoriatic arthritis, Publications, recommendation, risankizumab, secukinumab, tildrakizumab, tofacitinib, ustekinumab, Vaccination, vaccines

Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice Experiment

Armstrong AW, Bin Sawad A, Hazra NC, Balu S, Maslin D, Libchaber B, Huang R, Gauthier-Loiselle M, Guerin A. Patient Preferences for Treatment Attributes in[...]

A diagnostically challenging case of pemphigus foliaceus without histologic evidence of acantholysis

Liu JY, Scumpia P, Ni C, Yashar S, Langevin K, Kang Y, Vandiver A. A diagnostically challenging case of pemphigus foliaceus without histologic evidence of[...]

Response to Barnawi et al., “Bullous pemphigoid in the era of immunotherapy: Implications for treatment algorithms”

Kasperkiewicz M, Adotama P, Tomayko MM, Culton DA. Response to Barnawi et al., "Bullous pemphigoid in the era of immunotherapy: Implications for treatment algorithms". J[...]